Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Roflumilast in the Treatment of Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Chronic stable plaque psoriasis (min duration 6 months)~* PASI \>8~* Body mass index (BMI) \> 20 kg/m2~* Candidate for systemic treatment of psoriasis~* Negative pregnancy test (only women)~* Safe anticonception during entire study and at least 1 week after end of treatment (\~5 times plasma half-life of roflumilast) (only applying for fertile women)~Exclusion Criteria:~* Severe immunological disease, e.g. HIV, systemic lupus, and systemic sclerosis~* Current tuberculosis~* Current viral hepatitis~* Heart failure (NYHA III-IV)~* Moderate or severe liver failure (Child-Pugh B-C)~* Current or former malignancy (basal cell carcinoma excluded)~* Current or former depression with suicidal ideation~* Topical therapy for psoriasis during within 2 of randomization or during study~* Systemic therapy for psoriasis or psoriatic arthritis within 4 weeks of randomization or during study~* Treatment with theophylline, phenobarbital, carbamazepine, or phenytoin~* Confirmed pregnancy~* Planned pregnancy within 6 months~* Breast feeding~* Blood donation during study~* Inability to complete study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Roflumilast (Type: ACTIVE_COMPARATOR): Roflumilast 500 microgram daily (capsule)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (capsule)

Based on this trial design, predict the completion outcome and termination type (if applicable).